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Abstract: Mineralocorticoid receptor (MR)-mediated signaling in the brain has been suggested as a
protective factor in the development of psychopathology, in particular mood disorders. We recently
identified genomic loci at which either MR or the closely related glucocorticoid receptor (GR) binds
selectively, and found members of the NeuroD transcription factor family to be specifically associated
with MR-bound DNA in the rat hippocampus. We show here using forebrain-specific MR knockout
mice that GR binding to MR/GR joint target loci is not affected in any major way in the absence of MR.
Neurod2 binding was also independent of MR binding. Moreover, functional comparison with MyoD
family members indicates that it is the chromatin remodeling aspect of NeuroD, rather than its direct
stimulation of transcription, that is responsible for potentiation of MR-mediated transcription. These
findings suggest that NeuroD acts in a permissive way to enhance MR-mediated transcription, and
they argue against competition for DNA binding as a mechanism of MR- over GR-specific binding.
Keywords: basic-helix-loop-helix; brain; coactivator; glucocorticoids; hippocampus; mineralocorticoid
receptor knockout; stress; transcription biology
1. Introduction
The mineralocorticoid receptor (MR) regulates stress coping and has gained significant attention
in the field of psychopathology. In general higher brain MR expression levels or MR activity
parallel improved cognition and reduced anxiety [1]. An MR gain-of-function variant is associated
with optimism and provides a decreased risk for depression in females [2]. One single nucleotide
polymorphism (SNP) that is part of this haplotype affected the cortisol-awakening response only in
those subjects using antidepressants [3]. Furthermore, administration of an MR agonist as a supplement
to antidepressant therapy led to faster treatment response [4], and MR activation alone could improve
cognitive function in young depressed patients [5]. In contrast, chronic stimulation of the highly related
glucocorticoid receptor (GR) predisposes to stress-related disorders [6], and GR antagonism seems
of benefit in psychotic depression [7]. A study combining standard dexamethasone (GR activation)
for leukemia treatment with add-on cortisol (concurrent MR activation), shows that MR activity is
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important for neuronal processes such as sleep cycle and mood regulation [8]. Therefore, it is of great
relevance to characterize and enable selective modulation of MR-mediated effects, serving a potential
antidepressant approach.
Being part of the nuclear receptor family, MR and GR function as ligand-activated transcription
factors, binding the glucocorticoid response element (GRE) at the DNA to mediate transcriptional
changes. Even though the two receptors share their ligand cortisol/corticosterone (albeit with a
different affinity) and recognize the same motif, receptor-specific binding loci exist as demonstrated in
the rat hippocampus [9]. This suggests that other factors might be necessary to guide MR/GR-specific
binding and subsequent transcriptional effects. Indeed, we found that binding sites for NeuroD factors
were present selectively near MR-bound loci, and confirmed Neurod2 binding near MR-bound but not
GR-bound GREs [9]. Furthermore NeuroD factors were able to potentiate glucocorticoid-mediated
signaling in an in vitro setting, although MR/GR specificity was not recapitulated in reporter assays [9].
NeuroD proteins belong to the basic-helix-loop-helix (bHLH) family of transcription factors, and
regulate neuronal differentiation. Related MyoD factors are expressed in the muscle, where they induce
myogenesis. The bHLH transcription factors bind to E-boxes, which have the sequence CANNTG [10].
Specificity is obtained via the middle two nucleotides, with CAGATG known to be a NeuroD-specific
binding site, whereas CAGCTG is a shared site that is bound by both MyoD and NeuroD [11]. The
previously found interaction between NeuroD and glucocorticoid signaling was based on the presence
of the NeuroD-specific motif [9]. As the MyoD proteins are better understood in terms of functional
domains [12], we also examined transcriptional modulation by bHLH factors at the MyoD/NeuroD
shared motif to unravel the interaction between NeuroD and MR here.
The current study aimed to provide mechanistic insights in the NeuroD potentiation of MR
signaling, and how MR over GR specificity is achieved. We selected the protein Neurod2 as a
representative of the NeuroD family [9]. We first questioned whether GR binding would be affected by
MR absence, and if Neurod2 binding would be dependent on MR presence. Therefore, we assessed GR
and Neurod2 binding at previously identified MR targets [9] in the hippocampus of forebrain-specific
MR knockout mice (fbMRKO). Subsequently using various E-box binders in a reporter assay, we
further explored the mechanism by which NeuroD can enhance glucocorticoid signaling. Our data
show that at MR target loci both GR and Neurod2 binding seem independent of MR binding, and it is
likely the chromatin remodeling effect of NeuroD is responsible for the transcriptional potentiation.
2. Results
2.1. DNA Binding Assessed by Chromatin Immunoprecipitation
In order to define the mechanism behind the NeuroD potentiation of glucocorticoid signaling
in more detail, we first tested whether MR binding to its hippocampal DNA targets affects local
GR and Neurod2 binding. Although family members Neurod1, Neurod2 and Neurod6 are all
expressed in the adult mouse hippocampus and are able to bind the same NeuroD binding site [9],
we focus here on Neurod2. GR and Neurod2 occupancy of MR-binding loci was measured by
chromatin immunoprecipitation coupled with quantitative polymerase chain reaction (ChIP-qPCR) on
hippocampus of wild-type (WT) and forebrain-specific mineralocorticoid receptor knockout (fbMRKO)
mice. The fbMRKO mice show ablated hippocampal MR mRNA levels [13], which is accompanied
by efficient knockdown of MR protein (Bonapersona et al., in preparation). Plasma corticosterone
of all animals was over 140 ng/mL, ensuring ligand occupancy of both MR and GR [14]. No
difference in corticosterone plasma levels was observed between the two genotypes, with an average
of 363 ± 30 ng/mL for WT mice and 313 ± 44 ng/mL for fbMRKO mice (Figure 1A).
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Figure 1. ChIP-qPCR measurements for (A) GR and (B) Neurod2 in wild type (WT) and 97 
forebrain-specific MR knockout (fbMRKO) mice, and (c) their corticosterone levels. For each gene the 98 
corresponding IgG background signal is subtracted from detected binding levels, expressed as the 99 
percentage of immunoprecipitated DNA. The binding sites near Fkbp5, Klf9, Per1, Kif1c and Zfp219 100 
are joint MR/GR loci, while Rilpl1 has been identified as an MR-specific target [9]. Genes are further 101 
sorted based on the absence (Fkbp5, Klf9, Per1) or presence (Kif1c, Zfp219, Rilpl1) of a NeuroD binding 102 
sequence near the MR binding site. *** P<0.001 103 
2.1.2. MR effect on Neurod2 binding 104 
Next, we addressed the question whether the association between MR and NeuroD factors that 105 
we observed previously implies that Neurod2 binding at these loci depends on the presence of MR. 106 
We measured Neurod2 binding at the same loci as for GR binding. No Neurod2 binding motif was 107 
detected in the ChIP-identified MR-GR overlapping binding sequences near Fkbp5, Klf9 and Per1. For 108 
the Kif1c and Zfp219 associated MR-GR overlapping loci a directed motif search [9] did reveal a 109 
Neurod2 binding motif. Neurod2 binding was indeed observed for Kif1c, Zfp219 and to a lesser 110 
extent in Klf9, and for MR-specific Rilpl1 as observed before [9] (Figure 1B). Those genes with 111 
relatively low GR binding showed higher Neurod2 binding and vice versa, supporting the earlier 112 
finding that Neurod2 seems to interact preferentially with MR [9]. The fbMRKO mice demonstrated 113 
unchanged Neurod2 binding levels, indicating the presence of MR is not crucial for Neurod2 114 
binding. For Kif1c there might be an interaction, as the Neurod2 signal seems to be lower in fbMRKO 115 
compared to WT animals, but this difference does not statistically hold after multiple comparison 116 
Figure 1. (A) Corticosterone levels of wild-type (WT) and forebrain-specific mineralocorticoid
receptor (MR) knockout (fbMRKO) mice. In these mice chromatin immunoprecipitation coupled
with quantitative polymerase chain reaction (ChIP-qPCR) measurements fo (B) glucocorticoid rec ptor
(GR) and (C) Neurod2 we e performed. For e h gene, th corresponding immunoglobulin G
(IgG) back round signal is sub racted from d tected binding levels, expressed as the percentage
of immunoprecipitated DNA. The binding s tes near Fkbp5, Klf9, Per1, Kif1c and Zfp219 joint
MR/GR loci, while Rilpl1 has been identified as an MR-specific target [9] (separated by the right dotted
line). Ge es are further sorte based on the absence (Fkbp5, Klf9, Per1) or presence (Kif1c, Zfp219, Rilpl1)
of a NeuroD binding sequence near the MR binding site (separated by the left dotted line). *** p < 0.001
2.1.1. MR Effect on GR Binding
We aimed to investigate if the joint binding of MR and NeuroD on the DNA is related to
competition for GR binding at the same locus. GR binding was confirmed in WT mice for classical
glucocorticoid target genes Fkbp5 and Per1 (Figure 1B), which are occupied by both MR and GR [15].
Other MR-GR overlapping loci near the Klf9 [16] and Kif1c [9] genes showed evident GR binding.
Previously identified MR-specific target Rilpl1 [9] showed low GR signal, to the same extent as MR-GR
overlapping target Zfp219 [9]. GR binding levels were similar in the fbMRKO mice for most of the
genes measured, suggesting that GR binding is not dependent on MR binding at these target loci. Only
the GR binding at Per1 was slightly enhanced in MR absence (p = 0.00055), which might point to a
compensatory mechanism at this specific binding site. However, in general GR binding does not seem
to compensate for the lack of MR binding in fbMRKO mice.
2.1.2. MR Effect on Neurod2 Binding
Next, we addressed the question of whether the association between MR and NeuroD factors
that we observed previously implies that Neurod2 binding at these loci depends on the presence of
MR. We measured Neurod2 binding at the same loci as for GR binding. No Neurod2 binding motif
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was detected in the ChIP-identified MR-GR overlapping binding sequences near Fkbp5, Klf9 and Per1.
For the Kif1c and Zfp219 associated MR-GR overlapping loci a directed motif search [9] did reveal
a Neurod2 binding motif. Neurod2 binding was indeed observed for Kif1c, Zfp219 and to a lesser
extent in Klf9, and for MR-specific Rilpl1 as observed before [9] (Figure 1C). Those genes with relatively
low GR binding showed higher Neurod2 binding and vice versa, supporting the earlier finding that
Neurod2 seems to interact preferentially with MR [9]. The fbMRKO mice demonstrated unchanged
Neurod2 binding levels, indicating the presence of MR is not crucial for Neurod2 binding. For Kif1c
there might be an interaction, as the Neurod2 signal seems to be lower in fbMRKO compared to WT
animals, but this difference does not statistically hold after multiple comparison correction (p = 0.23).
Overall, these data show that Neurod2 binding to MR-associated loci is independent of MR binding.
2.2. Structure–Function Relationship
We continued unraveling the mechanism behind the NeuroD potentiation of glucocorticoid
signaling by exploring which coactivation property of the NeuroD protein is responsible for the
transcriptional potentiating effects. While the structure–function relationship of the NeuroD family
is not known in detail, much more is known about the related bHLH family of MyoD proteins [12].
We therefore used the myogenic regulatory factors MyoD and Myf5 as tools to study the effect of
bHLH factors in the potentiation of glucocorticoid signaling. Where MyoD can induce both histone
acetylation at H4 (chromatin remodeling) and in addition recruit RNA polymerase II (direct activation
mediated by the transcriptional activation domain), Myf5 is only able to induce H4 acetylation as
a manner to enhance transcription [12]. NeuroD family members have been shown to affect both
chromatin accessibility and direct transcriptional activation [11,17], although these functions have not
been assigned to a specific part of the protein. Comparing the myogenic variants will enable us to
dissect the process important for the potentiation of glucocorticoid signaling.
2.2.1. Transcriptional Potentiation by MyoD
We started by exploring whether MyoD is able to show a similar coactivation effect for
MR/GR-mediated signaling as Neurod2 did in our reporter assay. Despite the in vivo binding
selectivity of Neurod2 with MR (and not GR), Neurod2 exhibits coactivation of MR but also GR
transcriptional activity in vitro [9]. MyoD and NeuroD have both unique and common response
elements [11]. Our original reporter construct that is based on in vivo MR ChIP-sequencing binding
sites [9], harbors the NeuroD-specific CAGATG along a GRE. In a first experiment we tested the
effect of Neurod2, MyoD and a chimeric MyoD protein with its bHLH domain substituted by that
of Neurod2 (MyoD(ND2bHLH)) in the concentrations of 1–3–10 ng/well (Figure 2). Both a cofactor
(F2,24 = 356.3 for MR; F2,24 = 708.3 for GR, both p < 0.000001) and concentration (F3,24 = 247.6 for MR;
F3,24 = 489.0 for GR, both p < 0.000001) effect, plus an interaction (F6,24 = 71.0 for MR; F6,24 = 159.2 for
GR, both p < 0.000001) were observed.
We confirmed Neurod2 could potentiate glucocorticoid signaling for both MR and GR
(Figure 2A,B). The observed Neurod2 effect was receptor-mediated, as in absence or with lower
amounts of nuclear receptor expression vector Neurod2 did not enhance the glucocorticoid-dependent
transcriptional increase (Figure S1). We showed that also MyoD can potentiate MR- and GR-mediated
transcriptional activity, once brought to the DNA. Coactivation by MyoD itself is minimal with a
slightly higher fold induction in the upper tested dose compared to control cells without cofactor
(p = 0.0062 for MR; p = 0.0019 for GR), but can be enhanced to an extent similar to Neurod2 by
swopping the MyoD DNA-binding domain (DBD) with that of Neurod2 as demonstrated using the
MyoD(ND2bHLH) chimera (Figure 2). In its highest tested dose the chimera could even potentiate
glucocorticoid signaling to a superior extent. Of note, the chimera showed a clear dose-dependent
increase in potentiation over the concentration range tested. These findings indicate the Neurod2
DBD is required for coactivation, and the DNA sequence rather than the bHLH protein function
drives specificity.
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Figure 2. Specificity of NeuroD coactivation at the previously identified binding motif (CAGATG) 132 
for (A) MR and (B) GR. HEK293 cells were transfected with GRE-At_GA luciferase construct, MR or 133 
GR (10 ng/well), various amounts of Neurod2, MyoD or the MyoD/Neurod2 chimera 134 
(MyoD(ND2bHLH)) (0-1-3-10 ng/well), and stimulated with corticosterone (10-7 M). Data are 135 
presented as luciferase activity fold induction upon corticosterone treatment. a.u. = arbitrary unit; ** 136 
P<0.01, **** P<0.0001 compared to control condition; # P<0.05, ## P<0.01, ### P<0.001, #### P<0.0001 137 
for within group comparisons 138 
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Figure 2. Specificity of NeuroD coactivation at the previously identified binding motif (CAGATG) for
(A) MR and (B) GR. HEK293 cells were transfected with GRE-At_GA luciferase construct, MR or GR
(10 ng/well), various amounts of Neurod2, MyoD or the MyoD/Neurod2 c imera (MyoD(ND2bHLH))
(1–3–10 ng/well), and stimulat d with corticoster ne (10−7 M). Data are presented as luciferase activity
fold induction upon corticosterone treatment. a.u. = arbitr ry unit; ** p < 0.01, **** p < 0.0001 compared
to control condition; # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 for within group comparisons
2.2.2. Activation Domain Not Crucial for Potentiation
Finally we tested several bHLH factors for their coactivation ability in our reporter assay to
examine the contribution of different protein domains. In order to have a fair comparison of all variants,
we ensured a similar binding affinity of NeuroD and MyoD by further studying a reporter construct
containing the shared CAGCTG motif [11]. At this reporter Neurod2 and MyoD could potentiate MR
signaling to the same extent (Figure 3A), while for GR-mediated transcription the MyoD potentiation
was somewhat lower than by Neurod2 (p = 0.000003, Figure 3B). MyoD lacking its activation domain
(MyoD∆N) demonstrated a less strong potentiation of GR-mediated signaling compared to full length
MyoD (p = 0.0012), as did family member Myf5 (p = 0.0035), but both MyoD∆N (p = 0.047) and Myf5
(p = 0.016) still showed a significantly higher transcriptional effect upon corticosterone treatment than
the control condition without overexpression (Figure 3B).
The effect of the bHLH proteins on MR transactivation was more modest. Interestingly, the
MyoD∆N and Myf5 coactivating potential for MR-mediated signaling was not different from Neurod2
and MyoD (Figure 3A). However, MyoD∆N did not reach significance in corticosterone induction
compared to control cells (Figure 3A). Although potentiation of GR transcriptional activity by bHLH
factors seems thus partly dependent on their activation domain, these data suggest that the coactivation
of MR signaling by Neurod2 postulated to happen in vivo [9] is likely mediated via chromatin
remodeling rather than direct transcriptional activation.
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Figure 3. Modulation by NeuroD and MyoD variants at the shared binding motif (CAGCTG) for (A) 165 
MR- and (B) GR-mediated transcription. HEK293 cells were transfected with GRE-At_GC luciferase 166 
construct, MR or GR (10 ng/well), and Neurod2, MyoD, MyoDΔN or Myf5 (10 ng/well), and 167 
stimulated with corticosterone (10-7 M). Luciferase activity of nonstimulated control cells was 168 
normalized to 1. Numbers represent fold induction upon corticosterone treatment. a.u. = arbitrary 169 
unit; * P<0.05, ** P<0.01, **** P<0.0001 compared to control condition; #### P<0.0001 compared to 170 
Neurod2 condition; && P<0.01 compared to MyoD condition 171 
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Figure 3. Modulation by NeuroD and MyoD variants at the shared binding motif (CAGCTG) for (A)
MR- and (B) GR-mediated transcription. HEK293 cells were transfected with GRE-At_GC luciferase
construct, MR or GR (10 ng/well), and Neurod2, MyoD, MyoD∆N or Myf5 (10 ng/well), and stimulated
with corticosterone (10−7 M). Luciferase activity of nonstimulated control cells was normalized to 1.
Numbers represent fold induction upon corticosterone treatment. a.u. = arbitrary unit; * p < 0.05, ** p <
0.01, **** p < 0.0001 compared to control condition; #### p < 0.0001 compared to Neurod2 condition;
&& p < 0.01 compared to MyoD condition
3. Discussion
This study further elucidates the mechanism behind NeuroD potentiation of brain MR signaling.
First transcription factor DNA binding was assessed by ChIP-qPCR in mice lacking MR in (amongst
other brain regions) their hippocampus. Both GR and Neurod2 binding were not altered in these
fbMRKO mice compared to control mice, except for an enhanced GR signal at the Per1 promoter
in absence of MR. Subsequently bHLH factors of the NeuroD and MyoD families were used to
study coactivator effects in an MR/GR-driven reporter assay. Those factors lacking (MyoD∆N) or
with diminished (Myf5) activator function were able to potentiate the glucocorticoid-stimulated
transcriptional activation as well as Neurod2 and MyoD in case of MR-dependent transcription,
suggesting coactivation of MR signaling by Neurod2 does not require its activation domain.
3.1. Effects on DNA Binding
Because MR and GR can bind the same DNA sequences, GREs, the absence of MR might affect
genomic binding by GR. Competition between MR and GR at a specific locus does not seem to play a
major role, as there was no overall enhanced GR binding in the fbMRKO mice at the sites we examined,
even though hippocampal GR expression is upregulated in these animals [13,18]. Only in the case
of Per1, higher GR occupancy levels were observed at the promoter region in the absence of MR.
At this locus it has been demonstrated that besides homodimerization, MR and GR can combine to
form heterodimers [15]. However, we cannot distinguish between these two binding modes in our
measurements. The increased GR binding could reflect a compensatory mechanism to maintain a
required degree of Per1 expression and is in agreement with the fact that basal Per1 mRNA levels were
not altered in fbMRKO mice [13]. Rather than competition, data on joint occupancy suggest there can
be synergism between two transcription factors binding the same site, via a process called ‘assisted
loading’. For concurrent stimulation of the GR and estrogen receptor (ER; where ER is altered to also
recognize the GRE), GR activation could enhance ER binding at the same locus [19]. In the present
study, GR binding is not significantly diminished when MR is lacking, suggesting such assisted loading
is not applicable for MR-GR joint loci here. In our measurements of whole hippocampus we should
acknowledge that we work under the assumption that all studied cells have (similar amounts of) MR
and GR, but effects on DNA binding could be diluted as MR/GR expression is not homogeneous
throughout the hippocampal regions and in the various cell types present [20]. Single cell analysis will
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offer a solution to study transcription biology in a cell-type specific manner [21]. Nevertheless, our data
indicate that GR binding is predominantly independent from the presence of MR in the hippocampus.
In the same setting we studied if Neurod2 binding was affected by absence of MR. No differences
in Neurod2 signal at the MR target loci were observed in MR deficient mice, which implies that
NeuroD facilitates MR binding in a unidirectional manner. We cannot exclude the possibility that
Neurod2 binding is affected by or dependent on changes in stress hormone levels, since this was not
studied here. The presence of another collaborative transcription factor (nuclear factor-1) found near
preaccessible GR-bound loci was independent of corticosterone treatment or exposure to restraint
stress [22]. As discussed below, our reporter assay data suggest that the potentiation of MR signaling
by NeuroD is likely mediated via chromatin accessibility.
3.2. Mechanism of Glucocorticoid Signaling Potentiation
Unfortunately, the NeuroD activation domain is not well documented/distinguished, but MyoD
family members do have well described domains [12]. We first tested whether MyoD was able to
potentiate glucocorticoid signaling at a reporter construct containing a GRE and NeuroD-specific
E-box (CAGATG). When the MyoD DBD was adapted to that of Neurod2 in order to bind this motif
efficiently, MyoD could coactivate glucocorticoid-mediated signaling to a similar (or even superior)
extent as Neurod2. This is in line with findings by Fong et al., showing that MyoD could be redirected
to NeuroD target sites through replacement of its bHLH domain by the analogue sequence of Neurod2
and, hereby, could activate part of the neuronal differentiation program [23]. The same group has
demonstrated that NeuroD and MyoD can bind and drive transcription at the E-box that is specific
for the other bHLH factor, but have a strong preference for their specific motifs [11,23]. This explains
why unmodified MyoD showed a slight transcriptional potentiation on the NeuroD-specific binding
site at its highest concentration tested. In concordance with the DBD being decisive in converting
MyoD into a neurogenic factor [23], the specificity of the interaction between NeuroD/MyoD and
MR/GR in our data is also determined by the ability of the factor to bind the DNA rather than a
protein-specific functionality. Interactions between bHLH transcription factors and steroid receptors
can be speculated to be generic but have cell/tissue-type dependent mechanisms. For instance, bHLH
proteins DEC1/DEC2 (differentiated embryo chondrocyte) were found to corepress liver retinoid X
receptors [24]. Likewise, E47 can modulate hepatic glucocorticoid action by promoting GR occupancy
of metabolic target loci [25]. Of relevance in the testis, Pod-1 (also: transcription factor 21) could
diminish transactivation by the androgen receptor [26].
For unbiased comparisons we proceeded our experiments with a reporter construct containing
the shared E-box (CAGCTG), which is bound with similar affinity by both Neurod2 and MyoD [23].
Coregulators can modulate transcription by affecting chromatin accessibility and/or recruitment
and stabilization of the transcriptional machinery [27]. To distinguish between these two modes,
we made use of a truncated version of MyoD lacking its activation domain (responsible for direct
recruitment), and the myogenic Myf5 that has a weak activation domain (and, therefore, relies
mainly on its chromatin remodeling ability) compared to MyoD [12]. All MyoD variants were able
to coactivate the GRE-driven reporter. Strikingly, while potentiation of GR signaling was partly
dependent on the bHLH activation domain, coactivation of MR signaling was almost unaffected when
using the factors with diminished direct transcriptional activation. Extrapolating these findings to
the NeuroD family, the chromatin remodeling aspect of NeuroD thus seems sufficient for effective
potentiation of MR-mediated signaling. This is in accordance with the pioneer function of family
member Neurod1 demonstrated in a ChIP-sequencing experiment on developing neurons [17]. Of
note, during neurogenesis occupancy of the Neurod2-specific motif was linked to gene expression
effects, while the shared motif related mostly to chromatin modifications [11]. Despite the fact that
transient systems might be considered to have an undefined chromatin context, it has been shown that
exogenous plasmids do interact with endogenous histone proteins [28,29] and can serve as a proper
model to study effects mediated via chromatin accessibility as observed here.
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3.3. MR Selective Signaling and Future Implications
A number of issues have remained unaddressed. In the current study we have been looking at
only a subset of Neurod2 sites, and mainly focused on targets bound by both MR and GR. It would
be of interest to study genome-wide effects and observe if MR-specific sites become GR-bound in the
absence of MR. We also have to point out that we have not assessed in vivo which NeuroD factor(s)
is/are responsible for potentiation of MR signaling, as we only measured and detected Neurod2
binding at MR-bound sites [9]. The basis for MR over GR specificity in full chromatin is not known, but
the fact that bHLH chromatin remodeling plays a more important role in case of MR-mediated reporter
activation is in line with the fact that we could correlate MR and Neurod2 binding in vivo [9]. Besides,
those MR target genes with relatively low GR signal had high Neurod2 binding in our current ChIP
data. A study by Pooley et al. found that 17% of GR-bound loci contained a NeuroD binding site in
their vicinity [22]. These are likely MR/GR joint sites comparable to those studied here, some of which
do show an E-box and could be co-bound by Neurod2. MyoD family inhibitor domain-containing
protein (MDFIC) has been found to bind the hinge region of unliganded GR, is capable of regulating
GR phosphorylation and can by this means define the receptor transcriptome [30]. This interaction
might play a role in the MR/GR binding selectivity near Neurod2-bound sites, as our earlier studies
suggested that proteins in the nuclear receptor complex might account for the MR preference [9].
One promising approach to further elucidate the MR over GR specificity would be to have ChIP
experiments followed-up by proteomics [31].
The question emerges what the NeuroD potentiation of MR signaling implicates for stress
processing and stress-related disorders. Increased Neurod2 expression levels were detected in the
ventromedial prefrontal cortex of men with major depressive disorder compared to healthy control
subjects [32]. In a mouse model of chronic social defeat paradigm, overexpression of Neurod2 in
the ventral hippocampus reduces, while overexpression in the nucleus accumbens increases social
interaction time [33]. Antidepressant agomelatine could normalize the rise in hippocampal Neurod1
expression of mice that underwent chronic mild stress [34]. Furthermore, fish in touristic zones
were shown to express higher levels of Neurod1 and the MR gene Nr3c2 relative to fish at control
sites [35]. Together these observations strongly suggest a functional and context-dependent link
between NeuroD and stress regulation. How this might depend on MR or influence MR function
remains to be investigated. Further research is needed focusing on the in vivo specificity of the
interaction between MR and NeuroD, and directionality in the highly adaptable stress system. MR
activation is considered a promising strategy to promote stress resilience [1]. It would be of great
interest to test if SNPs in the MR gene can affect NeuroD potentiation. In conclusion, we show that
GR and Neurod2 binding at MR target loci is not dependent on MR presence and that Neurod2
potentiation of MR signaling is likely mediated via chromatin remodeling. We summarize the findings
of this study in Figure 4. Future studies will have to point out how the interaction between Neurod2
and MR might be exploited to modulate MR-specific effects in the brain and affect associated behavior.
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Figure 4. Summary of the interaction between hippocampal MR and NeuroD. Glucocorticoid
response elements (GREs) previously inaccessible (1) could be rendered accessible by chromatin
remodeling (one-way arrow) induced by NeuroD (2) binding at a nearby E-box (the NeuroD-specific
sequence CAGATG). Upon ligand availability MR can bind an accessible GRE (3) in order to modulate
transcriptional activity of its target genes. This interaction between NeuroD and MR (two-way arrow)
is likely mediated via additional TF(s) in the transcriptional complex [9]. In forebrain MR knockout
mice (4) GR is not compensating for the lack of MR binding at the MR-specific Rilpl1 site. Also at
several MR/GR joint target sites (5) NeuroD occupancy is observed in the vicinity. Of note, we cannot
discriminate between the binding of homo- and heterodimers in the present study. In absence of MR
(6) GR binding is increased at the Per1 promoter, while for the other tested loci GR binding levels
are unaltered. For sites that become GR-specific due to MR knockout, interactions with NeuroD
remain to be explored, and other TF(s) might be involved (?). MR = mineralocorticoid receptor, GR
= glucocorticoid receptor, GRE = glucocorticoid response element, TF = transcription factor, WT =
wild type
4. Materials and Methods
4.1. Animals
Male homozygous forebrain-specific MR knockout (MRflox/flox_Cre, fbMRKO, n = 9) and littermate
flox heterozygous control mice (MRflox/wt_wt, n = 10) [18] aged 10-19 weeks, were housed on a 12-h
light/12-h dark reversed cycle (lights off at 8:00AM). Mice were group-housed with fbMRKOs and
controls combined, and a total of four mice per cage. Each mouse was individually transferred to
a novel cage 45 min before harvesting the tissue, in order to ensure GR binding for ChIP analysis.
Mice were sacrificed by cervical dislocation around the time of their endogenous corticosterone peak,
between 9:00AM–11:30AM. Genotypes were equally distributed over the sacrifice window to prevent
an effect by time of the day. Trunk blood was collected, and hippocampal hemispheres were freshly
Int. J. Mol. Sci. 2019, 20, 1575 10 of 13
dissected, snap-frozen in liquid nitrogen and stored at −80 ◦C for later analysis. The experiment was
performed according to the European Commission Council Directive 2010/63/EU and the Dutch
law on animal experiments and approved by the animal ethical committee from Utrecht University
(authorization number 2014.I.08.057, approval date: 9 October 2014).
4.2. Plasma Corticosterone
Trunk blood was centrifuged for 10 min at 7000× g, after which plasma was transferred to new
tubes and stored at −20 ◦C for later analysis. Corticosterone levels were determined using an Enzyme
ImmunoAssay, according to the manufacturer’s instruction (Immunodiagnostic Systems, Boldon, UK).
4.3. ChIP-qPCR
To assess GR and Neurod2 binding at MR-bound loci, we performed ChIP-qPCR on hippocampal
tissue as described previously [9]. Briefly, two fixated hippocampal hemispheres of the same animal
were pooled and used for a single ChIP sample (500 µL) to measure GR binding (n = 4–5) with 6 µg
of anti-GR antibody H-300 (sc-8992X, Santa Cruz, Dallas, TX, USA) or Neurod2 binding (n = 4) with
6 µg of anti-Neurod2 antibody (ab109406, Abcam, Cambridge, UK). Hippocampi were allocated for
either GR or Neurod2 detection, with tissue from each group of co-housed mice divided over the
two transcription factors. A ChIP using 6 µg of control IgG antibody (ab37415, Abcam) was taken
along for background measurements, on a mixed hippocampal chromatin sample per genotype and
transcription factor. This was followed by qPCR on undiluted Chelex-isolated (200 µL) ChIP samples,
using the primers listed in Table 1.
Table 1. Primer sequences used for qPCR on mouse hippocampal ChIP samples. Primers target a
mineralocorticoid receptor binding site near the listed gene.
Gene Full Name Forward & Reverse (5′ > 3′) Product Length (bp)
Fkbp5 FK506 binding protein 5 TGCCAGCCACATTCAGAACATCAAGTGAGTCTGGTCACTGC 122
Kif1c Kinesin family member1C
GCTGGGGTGTACACAGATGG
TGACTAGCCAGAGCAGTATGTC 156
Klf9 Kruppel-like factor 9 ATCTAGGGCAGTTTGTTCAAGGCAGGTTCATCTGAGGACA 96
Per1 Period circadian clock 1 GGAGGCGCCAAGGCTGAGTGCGGCCAGCGCACTAGGGAAC 73
Rilpl1 Rab interactinglysosomal protein-like 1
CAGGCAGATGCCAGGCT
CCCATGCCTGTTCCTCTAGT 106
Zfp219 Zinc finger protein 219 AGTCCATCACATTCTGTTGCTTTCTAGTCAGCTATGACCATGCAGT 131
4.4. Reporter Assays
For mechanistic insights into the role of NeuroD factors on MR/GR-driven promoter activity, we
performed luciferase reporter as described previously [9]. In short, HEK293 cells were transfected
using FuGENE (Promega, Leiden, The Netherlands) with luciferase construct (GRE-At, 30 ng/well),
expression vector for either MR or GR (10 ng/well), with or without NeuroD/MyoD cofactor
(10 ng/well), and Renilla (1 ng/well) for normalization. To exclude glucocorticoid effects from the
medium we used charcoal-stripped fetal bovine serum (Sigma-Aldrich, Zwijndrecht, The Netherlands)
during the experiments. After 24 h stimulation of the cells with 10−7 M corticosterone (Sigma) reporter
protein levels were measured using the Dual Luciferase Reporter Assay System according to the
manufacturer’s instruction (Promega).
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4.5. Plasmids
Transcriptional activity was assessed at a GRE-driven promoter combined with either
the NeuroD-specific (CAGATG) or the MyoD/NeuroD-shared (CAGCTG) motif. The
GRE and NeuroD binding site-containing vector (GRE-At_GA) was constructed before
(GRE-At-pGL4 [9]). For the generation of the GRE-At_GC luciferase construct, we exploited
mutagenesis targeting the NeuroD binding site (GA > GC) using a QuikChange II Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). PAGE-purified mutagenic
primers were: 5′-CTCGAGGATGGCAGCTGGAGCTAAGAACAGAA-3′ and 5′-TTCTGTTCTTAG
CTCCAGCTGCCATCCTCGAG-3′. For MR and GR expression we used the 6RMR and 6RGR-based
plasmids [36]. Expression vectors (all pCS2) for Neurod2, MyoD, a chimera of MyoD with the
DNA-binding domain of Neurod2 (MyoD(ND2bHLH)), MyoD lacking the N-terminal domain
(MyoD∆N) and Myf5 were kindly provided by Dr. Tapscott [12,23].
4.6. Statistics
On the ChIP data we ran unpaired t-tests with the Holm–Sidak multiple comparison correction.
For the reporter assays we performed statistics on the fold induction by ligand (calculated for each
corticosterone-treated sample as signal in the presence of hormone divided by the average signal
from the same condition in absence of hormone). The first reporter experiment (different cofactors at
various concentrations) was analyzed by two-way analysis of variance (ANOVA); the second reporter
experiment (different cofactors) was analyzed by one-way ANOVA, both followed by Tukey’s post-hoc
tests. All data are presented as mean ± standard error of the mean.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/7/
1575/s1.
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